U.S. markets close in 6 hours 16 minutes
  • S&P 500

    4,454.38
    -28.35 (-0.63%)
     
  • Dow 30

    34,635.21
    -80.18 (-0.23%)
     
  • Nasdaq

    14,022.07
    -131.95 (-0.93%)
     
  • Russell 2000

    2,024.04
    -38.75 (-1.88%)
     
  • Crude Oil

    84.71
    -0.84 (-0.98%)
     
  • Gold

    1,841.50
    -1.10 (-0.06%)
     
  • Silver

    24.57
    -0.15 (-0.59%)
     
  • EUR/USD

    1.1353
    +0.0036 (+0.32%)
     
  • 10-Yr Bond

    1.7530
    -0.0800 (-4.36%)
     
  • GBP/USD

    1.3554
    -0.0046 (-0.34%)
     
  • USD/JPY

    113.7170
    -0.3830 (-0.34%)
     
  • BTC-USD

    38,581.70
    -4,127.86 (-9.66%)
     
  • CMC Crypto 200

    910.59
    +667.91 (+275.22%)
     
  • FTSE 100

    7,478.43
    -106.58 (-1.41%)
     
  • Nikkei 225

    27,522.26
    -250.67 (-0.90%)
     

Monte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • GLUE

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced members of its management team will be participating in the Piper Sandler 33rd Annual Virtual Healthcare Conference from Nov. 30-Dec. 2, 2021. The company’s pre-recorded fireside chat is available for registered attendees via the Piper Sandler conference site from Nov. 22-Dec. 2.

An archived webcast of the fireside chat can be accessed via the “Events & Presentations” section of the company’s investor site at https://ir.monterosatx.com/.

About Monte Rosa
Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader medicines. These medicines are designed to employ the body’s natural mechanisms to selectively eliminate therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates), that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, AI/machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. For more information, visit www.monterosatx.com.

Contacts:

Investors
Michael Morabito, Solebury Trout
ir@monterosatx.com

Media
Dan Budwick, 1AB
dan@1abmedia.com